Antithrombin-lowering in hemophilia: a closer look at fitusiran

Antithrombin-lowering in hemophilia: a closer look at fitusiran - Research and Practice in Thrombosis and Haemostasis

PDF) Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A

RNAi for the treatment of people with hemophilia

Gene therapy in haemophilia: literature review and regional perspectives for Turkey - Kaan Kavaklı, Bülent Antmen, Vahap Okan, Fahri Şahin, Selin Aytaç, Can Balkan, Ergül Berber, Zühre Kaya, Alphan Küpesiz, Bülent Zülfikar

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation

A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC

Summer 2022 haemophilia trial update - European Pharmaceutical Review

Full article: Current and emerging biologics for the treatment of hemophilia

International consensus recommendations on the management of people with haemophilia B - Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d'Oiron, Cédric Hermans, Victor Jiménez-Yuste, Adriana Linares, Tadashi Matsushita, Simon

HEMLIBRA: Potential Treatment for Hemophilia A Patients

Dosing of Fitusiran in U.S. Hemophilia Trials to Resume

siRNA against anti-thrombin reduces bleeding in hemophilia